Aprea Therapeutics Financials - Benzinga

Aprea Therapeutics Inc

APRENASDAQ

Trade with Public

Trade with Public

$0.8601

-0.12-12.23%

At close: Aug 27, 5:00 PM EST

$0.8800

0.01992.31%

After Hours: 7:51 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Stock Report

Aprea Therapeutics Financials

Aprea Therapeutics (APRE) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Aprea Therapeutics Q2 EPS $(0.07) Beats $(0.23) Estimate

Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.23) by 69.57 percent. This is a 86.79 percent increase over losses of $(0.53) per share

Benzinga Newsdesk

Earnings Scheduled For May 13, 2026

Benzinga Insights

PRO
Aprea Therapeutics Q1 EPS $(0.22) Beats $(0.23) Estimate

Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.23) by 4.35 percent. This is a 66.67 percent increase over losses of $(0.66) per share from

Benzinga Newsdesk

PRO
Aprea Therapeutics Q4 EPS $(0.32) Misses $(0.30) Estimate, Sales $3.337K Down From $205.817K YoY

Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.30) by 5.61 percent. This is a 34.69 percent increase over losses of $(0.49) per share

Benzinga Newsdesk

PRO
Aprea Therapeutics Q3 EPS $(0.47) Misses $(0.34) Estimate, Sales $1.848K Down From $354.621K YoY

Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.34) by 38.24 percent. This is a 26.56 percent increase over losses of $(0.64) per share

Benzinga Newsdesk

PRO
Aprea Therapeutics Q3 EPS $(0.47) Misses $(0.34) Estimate

Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.34) by 38.24 percent. This is a 26.56 percent increase over losses of $(0.64) per share

Benzinga Newsdesk